论文部分内容阅读
[目的]探讨血清CYFRA21 1对鼻咽癌的临床实用价值。[方法]采用IRMA法测定104例鼻咽癌患者、34例鼻咽其他疾病患者和65例健康对照者的血清CYFRA21 1含量。[结果]鼻咽癌组患者血清CYFRA21 1水平(5 48±6.12)ng/ml明显高于鼻咽其他疾病组(1.45±0.86)ng/ml及健康对照组(1.17±0.98)ng/ml,差异十分显著(P<0 001) ;并且鼻咽癌患者血清CYFRA21 1水平与其分期呈正相关(r=0 4341 ,t=4.87,P<0 001)。[结论]血清CYFRA21 1对鼻咽癌的诊断、分期、监测病情变化及与恶性淋巴瘤等其他疾病鉴别方面具有较高的临床实用价值。
[Objective] To investigate the clinical value of serum CYFRA21 1 in the treatment of nasopharyngeal carcinoma. [Method] The content of serum CYFRA21 1 in 104 patients with nasopharyngeal carcinoma, 34 patients with other diseases of the nasopharynx and 65 healthy controls were determined by IRMA. [Results] The serum level of CYFRA21 1 in nasopharyngeal carcinoma patients was significantly higher than that in other nasopharyngeal diseases (1.45 ± 0.86) ng / ml and healthy controls (1.17 ± 0.98) ng / ml, (5 48 ± 6.12) ng / The difference was significant (P <0.001). The serum level of CYFRA21 1 in nasopharyngeal carcinoma was positively correlated with its stage (r = 0 4341, t = 4.87, P <0.001). [Conclusion] Serum CYFRA21 1 has high clinical practical value in the diagnosis, staging, monitoring of disease progression and identification of other diseases such as malignant lymphoma.